Theranos Founder Elizabeth Holmes Appeals Conviction, Claims Key Evidence Was Fabricated

In a bold legal maneuver, former Theranos CEO Elizabeth Holmes is challenging her federal fraud conviction, arguing that a critical piece of evidence used against her was a “false claim.” The disgraced Silicon Valley entrepreneur, once hailed as the next Steve Jobs, filed an appeal seeking to overturn her 2022 guilty verdict.

Holmes’s legal team contends that testimony and documents related to Theranos’s flawed blood-testing technology were misleading. They specifically target evidence showing the company’s proprietary “Edison” devices produced wildly inaccurate results, which prosecutors said Holmes knowingly concealed from investors and patients. Her attorneys now assert this central pillar of the government’s case was fundamentally untrue.

The appeal marks the latest chapter in a saga that became a cautionary tale for tech hype. Theranos, founded in 2003, promised to revolutionize healthcare with technology that could run hundreds of diagnostic tests from just a few drops of blood. At its peak, the company was valued at $9 billion, with Holmes’s personal net worth estimated at $4.5 billion.

The house of cards collapsed following investigations by The Wall Street Journal and federal agencies, revealing the technology did not work as advertised. Holmes was convicted on four counts of defrauding investors out of more than $100 million. She began an 11-year prison sentence in May 2023 after losing an earlier bid to remain free during appeals.

Legal experts following the case express skepticism about the new claim’s chances. “This appears to be a last-ditch effort to reframe the established facts of the trial,” said a Stanford law professor not involved in the case. “The jury heard extensive testimony from whistleblowers, patients, and investors, and found the evidence of fraud overwhelming.” The Ninth Circuit Court of Appeals is expected to hear arguments later this year.